Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02363595 · ClinicalTrials.gov registry record
Genomic Predictors of Papillary Microcarcinoma Disease Progression
A clinical trial of Papillary Microcarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 750
- Enrollment target
- 1
- Study location
NCT02363595 is a study of Papillary Microcarcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 750 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02363595, a study of Papillary Microcarcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02363595
The ClinicalTrials.gov registry entry for NCT02363595 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papillary Microcarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT02363595 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02363595 about?
NCT02363595 is a clinical study titled "Genomic Predictors of Papillary Microcarcinoma Disease Progression". The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? Therefore, the purpose of this study is to identify specific clinical and molecular characteri...
What is the current status of trial NCT02363595?
This trial is currently recruiting. The enrollment target is 750 participants. The study started on 2014-12-31. Estimated completion is 2027-12-31.
What conditions does trial NCT02363595 study?
This clinical trial studies the following conditions: Papillary Microcarcinoma.
Who is sponsoring clinical trial NCT02363595?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02363595 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.